Skip to main content
. 2022 Sep 12;23:242. doi: 10.1186/s12931-022-02166-8

Table 2.

Pulmonary function test of patients at follow-up

First follow-up (2 months)
n = 377
Second follow-up (6 months)
n = 312
Third follow-up (12 months)
n = 284
p-value
FVC, L 3.50 (1.08) 3.55 (1.02) 3.66 (1.05) < 0.001
FVC, % pred 98.99 (17.86) 100.76 (16.49) 104.16 (16.10) < 0.001
FVC < 80%, pred 54 (14.32%) 29 (9.29%) 19 (6.69%) < 0.001
FEV1, L 2.79 (0.86) 2.81 (0.82) 2.89 (0.84) < 0.001
FEV1, % pred 98.58 (16.93) 100.12 (16.07) 103.53 (15.63) < 0.001
FEV1/FVC 79.58 (6.87) 79.03 (6.30) 78.75 (5.92) 0.004
DLCO, % pred 78.47 (19.14) 81.61 (16.37) 84.03 (16.37) < 0.001
DLCO < 80%, pred 203 (53.80%) 146 (46.79%) 113 (39.78%) < 0.001
DLCO/VA, % pred 92.55 (17.37) 95.20 (17.25) 95.66 (17.16) 0.001
DLCO/VA < 80%, pred 83 (22.02%) 57 (18.26%) 48 (16.90%) 0.02
TLC, % pred 95.61 (14.90) 96.47 (14.33) 96.88 (14.51) 0.08
RV, % pred 96.90 (23.65) 96.75 (23.18) 95.02 (23.80) 0.72
6MWT distance, m 523.63 (94.30) 520.57 (104.53) 518.82 (101.66) 0.004
mMRCa
 0–1 216 (78.54%) 244 (88.72%) 248 (90.18%) < 0.001
 ≥ 2 59 (21.45%) 31 (11.27%) 27 (9.82%)

Data are n (%) or mean (SD)

FVC forced vital capacity, FEV1 forced expiratory volume in one second, DLCO diffusing capacity for carbon monoxide, VA alveolar volume, TLC total lung capacity, RV residual volume, 6MWT 6 min walk test (m), mMRC modified British Medical Research Council (dyspnea)

aDyspnea was registered on 275 patients